Articles related to DEPRESSION

In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.

To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.

In this cross-sectional study of 586 probands and 698 first-degree relatives, cannabis use disorder and bipolar disorder II in probands were associated with an independent increase in risk of cannabis use disorder in relatives; bipolar disorder I and major depressive disorder in probands were not significantly associated with cannabis use disorder in relatives. The risk of cannabis use disorder was highest among relatives with both familial and individual history of bipolar disorder II.

Cannabis use increases the likelihood that patients will develop several negative health conditions, such as insomnia, anxiety, psychosis, and depression. As such, cannabis use should be prescribed carefully by physicians.

A new case study that analyzed the correlation between the use of antidepressants and suicide concluded that all patients treated with antidepressants should receive careful monitoring for clinical worsening, suicidality, or unusual changes in behavior.

There’s nothing like the sun when it comes to essential vitamin D. When your patients don’t get enough of it, fatigue and a host of other symptoms may arise. Here are 10 to keep an eye on if you think there may be a deficiency of vitamin D in your patients.